THC Science

Teneligliptin
Clinical data
Trade names	Tenelia
Legal status
Legal status	Approved in Japan;
Identifiers
	IUPAC name {(2S,4S)-4-[4-(3-Methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]-2-pyrrolidinyl}(1,3-thiazolidin-3-yl)methanone;
CAS Number	760937-92-6;
PubChem CID	11949652;
CompTox Dashboard (EPA)	DTXSID30997419 ;
Chemical and physical data
Formula	C22H30N6OS
Molar mass	426.58 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=NN(C(=C1)N2CCN(CC2)[C@H]3C[C@H](NC3)C(=O)N4CCSC4)C5=CC=CC=C5;
	InChI InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1; Key:WGRQANOPCQRCME-PMACEKPBSA-N;

Teneligliptin (INN; trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It was created by Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo in Japan.^[1]

References

@@ Line 44: / Line 44: @@
 }}
-'''Teneligliptin''' ([[International Nonproprietary Name|INN]]; trade name '''Tenelia''') is a pharmaceutical drug for the treatment of [[type 2 diabetes mellitus]].  It is approved for use in Japan.<ref>{{cite journal | journal = Annual Reports in Medicinal Chemistry | volume = 48 | pages = 523–524 | title = Teneligliptin (Antidiabetic) | chapter = To Market, To Market - 2012 | author = Joanne Bronson, Amelia Black, T. G. Murali Dhar, Bruce A. Ellsworth, and J. Robert Merritt | doi=10.1016/b978-0-12-417150-3.00028-4}}</ref>  It belongs to the class of anti-diabetic drugs known as [[dipeptidyl peptidase-4 inhibitor]]s or "gliptins".<ref>{{cite journal | pmid = 23671395 | year = 2013 | last1 = Kishimoto | first1 = M | title = Teneligliptin: A DPP-4 inhibitor for the treatment of type 2 diabetes | volume = 6 | pages = 187–95 | doi = 10.2147/DMSO.S35682 | pmc = 3650886 | journal = Diabetes, metabolic syndrome and obesity : targets and therapy}}</ref>
+'''Teneligliptin''' ([[International Nonproprietary Name|INN]]; trade name '''Tenelia''') is a pharmaceutical drug for the treatment of [[type 2 diabetes mellitus]].  It was created by [[Mitsubishi Tanabe Pharma]] and launched in September 2012 by both Mitsubishi Tanabe Pharma and [[Daiichi Sankyo]] in [[Japan]].<ref>http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006054.html</ref>
 ==References==